Clinical Trial Search

Primary: The Safety and Tolerability of CM4620-IE in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS) or Hypoxemia. — 7; 5; 3; 0…

Primary: Foot Care Behavior Score — 29; 36; 33; 42 Participants — p=0.0770

Primary: PTSD Symptoms Using PTSD Checklist-5 (PCL-5) at Baseline and 15 Days — 33.2; 36.6; 31.2; 28.2 units on a scale — p=0.322

Primary: Pain Scores (Numerical Rating Scale 0-10) Using the Faces Pain Scale-Revised — 5; 3.4 Units on a scale

Primary: Pain Score During Ablation — 24; 20 Units on a scale

Primary: Part A: Number Of Participants Experiencing Adverse Events (AEs) — 12; 12; 6; 13 Participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug — 0; 0; 0; 0 Participants

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Tlast (AUC[0-tlast]) of LY3832479 — 1560; 4530 microgram*day per milliliter…

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3819253 — NA; 918; 1390 micrograms*day per…

Primary: Parkinson's Disease Symptoms — 52.5 units on a scale

Primary: Change From Baseline in WOMAC VA3.1 Pain Subscale Score at Month 6 — -23.6; -14.1 mm — p=0.141

Primary: Event Rate Per 100 Participant-Years For First Occurrence of Major Bleeding Events After Index Date in Obese Participants — 7.27; 4.06 Events Per 100 Participant-Years…

Primary: Post Operative Outcomes — 27; 0; 6; 4 participants

Primary: Percentage of Participants Who Experienced an Adverse Event (AE) up to Day 56 — 92.9; 92.9; 91.7; 62.5 Percentage of Participants — p== 0.2003

Primary: Change From Baseline to Follow-up in Health Related Quality of Life — 0.059; 0.055 score on a scale